诺和龙治疗2型糖尿病合并动脉粥样硬化患者的临床疗效观察

目的观察探讨瑞格列奈(诺和龙)治疗2型糖尿病合并动脉粥样硬化患者的临床疗效。方法选取2009年3月～2011年3月112例糖尿病合并动脉粥样硬化的患者,随机分为观察组和对照组,各56例,观察组采用诺和龙治疗,对照组采用格列吡嗪(优哒灵)治疗,观察比较两组疗效。结果两组治疗前后的空腹血糖(FBG)、糖化血红蛋白(HbA1C)及餐后2h血糖(2hPBG)比较存在明显差异,观察组降低幅度更为明显(P<0.05),具有统计学意义。结论诺和龙治疗2型糖尿病合并动脉粥样硬化患者的临床疗效显著,能够给有效降低血糖,改善动脉粥样硬化的各项指标。

Objective To evaluate the repaglinide in the treatment of type 2 diabetic patients with atherosclerosis：clinical curative effect.Methods In our hospital from March 2009 to March 2011,112 cases of diabetes mellitus complicated with atherosclerosis patients,were randomly divided into the observation group and the control group,56cases each,the observation group was treated with repaglinide in the treatment,control group with gliclazide treatment,observation of curative effects of two groups were compared.Results The two groups before and after treatment（FBG）,fasting blood glucose,glycosylated hemoglobin（HbA1C） and 2h postprandial plasma glucose（2hPBG） more obvious difference,the observation group reduced amplitude is more obvious（P〈0.05）,with statistical significance.Conclusion Repaglinide in treating type 2 diabetes with atherosclerosis in patients with significant clinical effect,can effectively reduce blood sugar,improve atherogenic index.